LEAP-005 investigators tested the safety and efficacy of combination lenvatinib and pembrolizumab in 32 patients with previously treated advanced non–microsatellite instability-high (MSI-H)/mismatch repair proficient (pMMR) colorectal cancer (CRC).
Investigators reviewed data from 202,237 patients from the Surveillance, Epidemiology, and End Results (SEER) registry who had been diagnosed CRC with 2010 and 2015.
Using data from the Minnesota Colon Cancer Control Study, a team of investigators assessed the impact of polypectomy on the incidence of colorectal cancer.
Investigators found a high prevalence of clinically relevant colorectal diseases and cancer among patients undergoing colonoscopy when quality parameters were emphasized.
The “watch and wait” approach is characterized by close surveillance without surgery in patients with rectal cancer who achieve a clinical CR following neoadjuvant CRT.
Incidence of early-onset CRC found more prevalent in some US regions referred to as “hot spots.”
Medicaid expansion also may result in improved access to treatment, including palliative care.
Mortality reduced for patients with newly diagnosed breast, colorectal, lung cancers, mediated by earlier stage of diagnosis.
Neoadjuvant RT recommended for stage II to III rectal cancer; RT should be performed preoperatively.
Benefit substantial for adults aged 50 to 75 years; benefit moderate for adults aged 45 to 49 years.
